NanoViricides files prospectus for $2.375M common stock offering

0 min read | Published on 21 Oct 2026, 08:15 PM |Updated on 21 Oct 2026, 08:15 PM

Reviewed by

Riya DScanX News Team

Add as a preferred
source on Google

Key Highlights

NanoViricides Inc. filed a prospectus for a $2.375 million common stock offering
The filing was submitted to the SEC under Form 424B5
The offering involves the sale of common stock securities

*this image is generated using AI for illustrative purposes only.

NanoViricides Inc. (NASDAQ: NVRX) has filed a prospectus with the U.S. Securities and Exchange Commission (SEC) to offer $2.375 million in common stock. The filing, submitted under Form 424B5, outlines the terms of the proposed equity issuance.

The document specifies the offering size as $2.375 million. No further financial metrics, such as pricing per share or use of proceeds, were detailed in the available excerpt of the filing.

Offering details

The prospectus relates to the sale of common stock by the company. Key data points from the filing include:

Item	Detail
Company	NanoViricides Inc.
Filing Type	Prospectus (Form 424B5)
Offering Value	$2.375 million
Security Type	Common Stock

Disclaimer: This article is AI-generated using data from ViewTrade. ScanX is not liable for any inaccuracies.

How will the dilution from this $2.375 million equity issuance impact NVRX's existing shareholder value?

What specific clinical milestones or operational needs will the proceeds from this offering fund?

How might this capital raise affect NanoViricides' ability to secure future non-dilutive financing or partnerships?

Nanoviricides Q4 Results: Loss narrows 23% YoY to $(0.10) per share

0 min read | Published on 29 Sept 2026, 03:24 AM |Updated on 29 Sept 2026, 03:24 AM

Reviewed by

Shriram SScanX News Team

Add as a preferred
source on Google

Key Highlights

Nanoviricides posted a Q4 loss of $(0.10) per share
The figure met the analyst consensus estimate
Losses narrowed by 23.08% from $(0.13) in the prior year

*this image is generated using AI for illustrative purposes only.

Nanoviricides (AMEX: NNVC) reported a fourth-quarter loss of $(0.10) per share, meeting the analyst consensus estimate. The result represents a 23.08% reduction in losses compared to the same period last year.

Quarterly Performance Overview

The biotechnology company narrowed its per-share deficit significantly year-over-year. While the loss remains in negative territory, the magnitude of the shortfall decreased from $(0.13) in the prior year's corresponding quarter.

Metric	Current Quarter	Prior Year Quarter	Change
Earnings Per Share	$(0.10)	$(0.13)	+23.08%
Analyst Consensus	$(0.10)	N/A	Inline

What the Numbers Show

The data indicates a clear trend of loss reduction. The company improved its bottom line by narrowing the loss per share by 23.08%. Importantly, the reported figure of $(0.10) aligned exactly with market expectations, suggesting that the operational performance was in line with what investors had priced into the stock.

Disclaimer: This article is AI-generated using data from ViewTrade. ScanX is not liable for any inaccuracies.

What specific operational cost reductions or pipeline milestones drove the 23% narrowing of losses in Q4?

How does the current cash burn rate impact Nanoviricides' runway and potential need for dilutive financing in the next 12 months?

What are the projected timelines for key clinical trials that could shift the company from loss reduction to revenue generation?